Memory Reconsolidation Blockade for Treating Drug Addiction

Status Completed

Clinical Trial Summary

The treatment involves administering propranolol, a medication indicated for treating high blood pressure. Propranolol is hypothesized to reduce the strength of drug or alcohol cravings (an integral factor involved in relapse), specifically when memories of substance use are recalled. In this study, propranolol or a placebo will be administered to patients participating in a drug or alcohol rehabilitation facility once a week over three or six weeks. After receiving propranolol or placebo, strong memories associated with substance craving are recalled by asking participants to read aloud a summary of a substance use experience. The investigators hypothesize that participants who receive propranolol will report fewer and less intense drug or alcohol cravings than participants who receive the placebo or treatment-as-usual.

Clinical Trial Description

Trial Objectives: To test the feasibility of reconsolidation blockade as an adjunct treatment for reducing drug or alcohol cravings in individuals diagnosed with a substance dependence or substance abuse disorder and participating in a drug rehabilitation program.

Study Design and Duration: This study will be a 3 to 6 week, randomized, double-blind trial involving participants with a DSM-IV-TR diagnosis of substance dependence or abuse. Consented participants meeting enrolment criteria will receive a dose of propranolol (1mg/kg) or placebo ninety minutes before undergoing a brief memory reactivation procedure twice a week for a three-week period (or once a week for a six week period, depending on the participants availability) as an adjunct to their usual drug rehabilitation treatment. Participants will be randomized to one of two treatment arms (i.e. placebo group + treatment as usual, or propranolol group + treatment as usual) and remain in that arm for the duration of the study. Participants from the placebo arm will be offered the opportunity to continue receive open-label propranolol treatment for another 3-6 weeks following the double-blind phase of the study. A four-month follow-up assessment will also be conducted. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01634347
Study type	Interventional
Source	Douglas Mental Health University Institute
Contact
Status	Completed
Phase	Phase 2
Start date	January 2012
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00887367` - EtOH Interaction Study	Phase 1
Completed	`NCT01036061` - GSK618334 Repeat Dose Study	Phase 1
Completed	`NCT01189799` - Motivational Therapy for Substance Users With Depression	N/A
Completed	`NCT01381133` - Adolescent Outpatient and Continuing Care Study	Phase 3
Recruiting	`NCT04430257` - Pre-exposure Prophylaxis (PrEP) for Health	N/A
Completed	`NCT01128140` - Efficacy Trial of Warrior Check-Up	Phase 2
Completed	`NCT03767907` - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial	N/A
Recruiting	`NCT05833399` - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn	`NCT01515917` - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)	N/A
Completed	`NCT00208143` - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia	Phase 4
Withdrawn	`NCT03762798` - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone	N/A
Completed	`NCT03048552` - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3	N/A
Active, not recruiting	`NCT04768920` - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)	N/A
Recruiting	`NCT05410561` - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients	N/A
Recruiting	`NCT05679284` - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn	`NCT00908206` - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics	Phase 1
Recruiting	`NCT05348317` - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders	N/A
Recruiting	`NCT01741415` - Distress Tolerance Treatment for Substance Users	Phase 2
Active, not recruiting	`NCT01621711` - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care	N/A
Active, not recruiting	`NCT00609089` - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.